XML 90 R82.htm IDEA: XBRL DOCUMENT v3.22.2.2
Product and Geographic Sales Information - Adjusted EBITDA by Segment (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information [Line Items]                
Total Adjusted EBITDA $ 271.6     $ 190.0     $ 808.3 $ 543.8
Provision for income taxes (22.1)     (3.7)     (48.9) (12.2)
Depreciation and amortization 169.7     130.7     521.7 392.6
Interest expense and amortization of debt discount, net (71.5)     (65.3)     (193.3) (141.2)
Fair Value Adjustment of Warrants 53.3     83.0     202.7 113.2
Deferred revenues adjustment(2) (0.3)     (0.1)     (0.9) (4.5)
Business Combination, Acquisition Related Costs (3.7)     16.4     8.1 7.4
Share-based compensation expense (20.8)     (10.6)     (79.9) (107.7)
Restructuring and impairment 26.0     7.1     56.9 125.7
Other(5) 14.9     (10.7)     63.7 (24.8)
Net (loss) income (4,415.5) $ 62.4 $ 69.5 28.4 $ (131.5) $ (56.0) (4,283.6) (159.1)
Dividends on preferred shares (18.9)     (22.4)     (56.3) (22.4)
Net income (loss) attributable to ordinary shares (4,434.4)     6.0     (4,339.9) (181.5)
Goodwill, impairment loss (4,448.6)           (4,448.6)  
Life Sciences and Healthcare                
Segment Reporting Information [Line Items]                
Total Adjusted EBITDA 41.5     32.2     125.4 92.3
IP Segment                
Segment Reporting Information [Line Items]                
Total Adjusted EBITDA 106.0     98.1     331.4 282.5
Academia & Government                
Segment Reporting Information [Line Items]                
Total Adjusted EBITDA $ 124.1     $ 59.7     $ 351.5 $ 169.0